Articles tagged with Drug Combinations
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers have discovered a new mechanism for starving pancreatic cancer cells, potentially leading to improved treatment outcomes. A combination of treatments involving the drug DRP-104, which blocks glutamine metabolism, and trametinib, an existing ERK signaling pathway blocker, showed promising results in mouse models.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A study at Ohio State University found that a combination of ibogaine hydrochloride and 5-MeO-DMT significantly improved PTSD symptoms, depression, anxiety, and cognitive functioning in special operations forces veterans. The treatment also alleviated cognitive impairment linked to traumatic brain injury.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
A study showed that yoga therapy can improve heart failure patients' endurance, strength, balance, symptom stability, and overall quality of life. Additionally, echocardiographic parameters revealed improved left ventricular systolic function in the yoga group compared to the non-interventional group.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
Researchers at the University of Cambridge have made a groundbreaking discovery that could lead to more effective treatments for neuroblastoma, a devastating form of childhood cancer. The new approach uses a combination of two drugs to encourage cancer cells to become normal non-dividing cells, potentially reducing side effects.
US overdose deaths involving fentanyl and stimulants increased 50-fold from 2010 to 2021, with stimulants becoming most common drug class found in fentanyl-involved overdoses. The trend disproportionately affects racial/ethnic minority communities, particularly Black and African American people.
US overdose deaths involving fentanyl and stimulants have increased by 50-fold since 2010, with stimulants becoming the most common drug class found in fentanyl-involved overdoses. The rise poses new challenges for healthcare providers due to the complexity of treating polysubstance use.
Patients with stage 1-3 non-small cell lung cancer treated with combination immunotherapy before surgery had a better major pathological response rate than those receiving single-agent therapy alone. The NeoCOAST platform trial found that targeting multiple cancer pathways through therapy may be superior to a single treatment.
A comprehensive global analysis found that these stop-smoking aids are nearly twice as effective as single forms of NRT. Dual forms of NRT, such as combining a patch with gum or a lozenge, were found to be nearly as effective as nicotine e-cigarettes and prescription medications.
A Texas A&M University team is exploring 3D printing to create tailored medication dosage and tablet size for young children, addressing the need for greater flexibility in administering medications. The project aims to maintain drugs' integrity and effectiveness while advancing the field of pharmaceutical manufacturing.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
The new microscope uses structured illumination and optical fibers to achieve fast super-resolution imaging over a wide field of view, enabling the study of individual cell responses to various drugs. The system can image multiple cells simultaneously with high resolution, providing statistical information about cell response.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
Researchers at the Institute for Systems Biology have identified a signaling system called MtrA that helps Mycobacterium tuberculosis grow in response to host signals. Disrupting this system compromises the pathogen's cell wall, making it unable to divide and ultimately compromising its survival.
A new drug formulation designed for treating children with HIV has shown safety, tolerability, and effectiveness in a study published in The Lancet HIV. The formulation contains three medications and was found to suppress HIV levels below 200 copies/mL in 98% of participants.
A new study uses machine learning to analyze data from DrugAge, a database of chemical compounds modulating lifespan in model organisms. The researchers create four types of datasets to predict whether or not a compound extends the lifespan of C. elegans, using features such as compound-protein interactions and Gene Ontology terms.
The American Heart Association and the American College of Cardiology recommend a heart-healthy diet and lifestyle to prevent worsening health in people with chronic coronary disease. Clinicians should coordinate care between cardiovascular and primary care professionals, emphasizing team-based approach and social determinants of health.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
Researchers found that a triple combination therapy of elexacaftor, tezacaftor, and ivacaftor improves lung function and reduces inflammation in patients with cystic fibrosis. The treatment's positive effects last over 12 months, offering hope for better management of the disease.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
A new molecular compound has been identified that can activate latent HIV-1 in cells, showing promise for HIV treatments. Researchers found that this compound, YSE028, can reactivate latently infected cells and induce cell death, potentially leading to a complete cure for HIV.
Researchers found that combining radiation with a genetically engineered oncolytic vaccinia virus improved treatment outcomes for glioblastoma brain tumors in mice. The combination showed a 15% cure rate and 62% rejection of new cancer cells, outperforming radiation alone.
A machine-learning study has found that individual characteristics, including age and weight, determine which drug combinations most effectively reduce COVID-19 recurrence rates. The study used real-world data from a hospital in China and identified unique treatment combinations for different demographic groups.
A retrospective study found a 24% response rate to Docetaxel among patients with stage IV non-small cell lung cancer who experienced progression on immunotherapy. The median progression-free survival was 3 months, suggesting chemotherapy may still play an important role in treatment after immunotherapy failure.
LSU Health New Orleans researchers found that a combination therapy using Neuroprotectin D1 and Resolvin D1 boosted brain cell survival, growth, and stability. The therapy showed promising results in reducing lesion volume and improving neurological function in acute ischemic stroke models.
Researchers discuss chemotherapeutic resistance in recurring ovarian cancer, focusing on the unfolded protein response and its effect on polyploid giant cancer cells. Understanding this mechanism could lead to investigating cancer cell molecular mechanisms and potential therapeutic strategies.
Researchers at USC Norris Comprehensive Cancer Center have identified a biomarker, CX3CR1, that can predict which patients with non-small cell lung cancer will respond well to chemoimmunotherapy. Elevated levels of the biomarker in T-cells after six to nine weeks of treatment indicate long-term benefits from the combination therapy.
Researchers from Amsterdam UMC and Copenhagen University have found that a chemofree drug-combination therapy is more effective than traditional chemotherapy in treating CLL, resulting in reduced side effects and improved patient outcomes. The study, the largest ever conducted on CLL, involved 920 fit patients and showed that treatment...
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer, with patients experiencing significantly improved progression-free survival. The median PFS was 11.3 months for those on nivolumab and ipilimumab alone, compared to not yet reached in the three-drug group.
A recent clinical trial showed that cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer, improving their quality of life. The treatment also reduced symptoms such as pain and cough, and delayed clinically meaningful deterioration.
A pilot study found that high-dose tadalafil improved metabolic control and reduced hemoglobin A1c levels by 2.50 mmol/mol in patients with well-controlled type 2 diabetes. The treatment also showed increased blood flow, liver values, and metabolism.
A majority of people over 50 are open to stopping one or more prescription medicines, but many don't discuss it with their health provider first. The poll shows that comprehensive medication reviews and cost considerations play a crucial role in deprescribing conversations.
Researchers found that removing ovaries during a benign hysterectomy increases the risk of hospitalization for cardiovascular disease in premenopausal women, but not necessarily for cancer. The study supports current recommendations to conserve ovaries in premenopausal patients at low risk for ovarian cancer.
Researchers have identified a promising new combination of drugs to treat juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer affecting children. The combination of 5-azacitidine and MEK inhibitor PD0325901 reduced cancerous stem cells and improved blood cell abnormalities.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
Researchers at University of California San Diego School of Medicine found a significant reduction in disease growth when combining immunotherapy with chemotherapy in patients with advanced endometrial cancer. The study resulted in a 70% risk reduction in the deficient mismatch repair group.
A Phase II trial led by researchers from the University of Texas MD Anderson Cancer Center demonstrated that adding ipilimumab to a neoadjuvant combination of nivolumab plus platinum-based chemotherapy resulted in a major pathologic response in half of all treated patients with early-stage non-small cell lung cancer. The treatment also...
A multicenter study found that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement. This breakthrough therapy has improved the quality and length of patients' lives, with some even seeing a 15% increase in lung function.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
A new study by Weill Cornell Medicine found that the FDA's mandate to limit opioid-acetaminophen combinations resulted in significant reductions in liver injuries. The mandate, implemented in 2014, limited the dosage of acetaminophen in these drugs, leading to a decline in hospitalizations and acute liver failure cases.
A US FDA mandate to limit acetaminophen dosage in pills combining it with opioids significantly reduced hospitalizations and acute liver failure cases. Researchers found a persistent decline in yearly rates of these cases after the mandate was implemented in 2014.
A virtual care team consisting of physicians and pharmacists improved the adoption of life-saving therapies in patients with heart failure, leading to increased use of evidence-based treatments and better patient outcomes. The strategy was safe and effective, with comparable length of stay and safety events between the groups.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
A systematic review of 18 studies found that muscle relaxants and non-steroidal anti-inflammatory drugs (NSAIDs) can effectively reduce symptoms. Combining NSAIDs with paracetamol showed a greater improvement than using NSAIDs alone.
A groundbreaking study found that a new TB treatment strategy can shorten treatment duration while maintaining effectiveness. The TRUNCATE-TB trial showed that an initial 8-week treatment period followed by retreatment for those not cured was as effective as the standard 6-month treatment but halved the average total time on treatment.
Researchers at VCU Massey Cancer Center have discovered a novel combination therapy that dramatically suppresses the growth of AML cells, including those resistant to venetoclax. The dual mTORC1/2 inhibitors synergistically enhance AML cell death when paired with venetoclax.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.
Scientists at MIT have designed a novel nanoparticle platform that can deliver optimal ratios of multiple cancer drugs, leading to enhanced efficacy and reduced side effects. The bottlebrush-shaped particles can be loaded with varying concentrations of drugs, enabling the precise delivery of synergistic combinations.
A combination of two novel immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer. The study found that 23% of patients had a tumor reduction, and the disease control rate was 76%. The treatment was well-tolerated, but adverse events were common.
Researchers discovered a drug combination that targets immune evasion pathways in MYC amplified Medulloblastoma, a fatal childhood brain cancer. The treatment uses epigenetic drugs to unblock 'don't eat me' pathways and make tumors more appealing to macrophages.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
A new multidrug treatment combining pembrolizumab and all-trans retinoic acid has proven effective in treating stage IV melanoma, with an overall response rate of 71% and a one-year overall survival rate of 80%. The study's results are promising for patients who have failed traditional immunotherapy.
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.